PMID- 37878770
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1876-4479 (Electronic)
IS  - 1873-9946 (Print)
IS  - 1873-9946 (Linking)
VI  - 18
IP  - 3
DP  - 2024 Mar 1
TI  - Matrix metalloproteinases in intestinal fibrosis.
PG  - 462-478
LID - 10.1093/ecco-jcc/jjad178 [doi]
AB  - Intestinal fibrosis is a common complication in patients with inflammatory bowel 
      disease [IBD], in particular Crohn's disease [CD]. Unfortunately, at present 
      intestinal fibrosis is not yet preventable, and cannot be treated by 
      interventions other than surgical removal. Intestinal fibrosis is characterized 
      by excessive accumulation of extracellular matrix [ECM], which is caused by 
      activated fibroblasts and smooth muscle cells. Accumulation of ECM results from 
      an imbalanced production and degradation of ECM. ECM degradation is mainly 
      performed by matrix metalloproteinases [MMPs], enzymes that are counteracted by 
      tissue inhibitors of MMPs [TIMPs]. In IBD patients, MMP activity [together with 
      other protease activities] is increased. At the same time, CD patients have a 
      generally lower MMP activity compared to ulcerative colitis patients, who usually 
      do not develop intestinal strictures or fibrosis. The exact regulation and 
      role[s] of these MMPs in fibrosis are far from understood. Here, we review the 
      current literature about ECM remodelling by MMPs in intestinal fibrosis and their 
      potential role as biomarkers for disease progression or druggable targets.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of European 
      Crohn's and Colitis Organisation.
FAU - Biel, Carin
AU  - Biel C
AUID- ORCID: 0000-0002-0599-1857
AD  - Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 
      the Netherlands.
FAU - Faber, Klaas Nico
AU  - Faber KN
AD  - Department of Gastroenterology and Hepatology, University Medical Center 
      Groningen, Groningen, The Netherlands.
FAU - Bank, Ruud A
AU  - Bank RA
AD  - Department of Pathology and Medical Biology, University of Groningen, University 
      Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
FAU - Olinga, Peter
AU  - Olinga P
AUID- ORCID: 0000-0003-4855-8452
AD  - Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 
      the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - J Crohns Colitis
JT  - Journal of Crohn's & colitis
JID - 101318676
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Humans
MH  - Intestines
MH  - *Crohn Disease/metabolism
MH  - *Inflammatory Bowel Diseases
MH  - Fibrosis
MH  - Matrix Metalloproteinases/metabolism
PMC - PMC10906956
COIS- There are no conflicts of interest to declare.
EDAT- 2023/10/25 18:42
MHDA- 2024/03/04 06:43
PMCR- 2023/10/25
CRDT- 2023/10/25 14:43
PHST- 2023/02/20 00:00 [received]
PHST- 2023/10/03 00:00 [revised]
PHST- 2023/10/24 00:00 [accepted]
PHST- 2024/03/04 06:43 [medline]
PHST- 2023/10/25 18:42 [pubmed]
PHST- 2023/10/25 14:43 [entrez]
PHST- 2023/10/25 00:00 [pmc-release]
AID - 7329683 [pii]
AID - jjad178 [pii]
AID - 10.1093/ecco-jcc/jjad178 [doi]
PST - ppublish
SO  - J Crohns Colitis. 2024 Mar 1;18(3):462-478. doi: 10.1093/ecco-jcc/jjad178.